The American Board of Ophthalmology (ABO) is pleased to announce the appointment of Hans E. Grossniklaus, MD, MBA, to its Board of Directors for a term beginning January 1, 2021. The nation’s first medical specialty board, the ABO develops rigorous assessments for the certification of eye physicians and surgeons in the United States. Since 1916, more than 32,000 physicians have demonstrated their knowledge and skills in ophthalmology through ABO certification.
As a Director of the ABO, Dr. Grossniklaus will apply his ophthalmic expertise to the development of professional standards designed to protect the well-being of eye care patients. Over 104 years, fewer than 200 ophthalmologists have been selected for this prestigious leadership role at the ABO—a physician-led, not-for-profit organization.
Professor and Vice Chair of Translational Research at Emory Eye Center, Dr. Grossniklaus is the founding director of the ocular oncology and pathology service and director of the pathology laboratory. Dr. Grossniklaus completed his medical degree at Ohio State University, residencies in ophthalmology and pathology at Case Western Reserve University, and fellowships at Wilmer Institute and the Armed Forces Institute of Pathology. He currently serves as the Executive Vice President of the American Ophthalmological Society (AOS).
“Dr. Grossniklaus brings a remarkable portfolio to the Board of Directors,” said ABO Chief Executive Officer George B. Bartley, MD. “A world-renowned ophthalmic pathologist with board certification in each specialty, Dr. Grossniklaus possesses MBA training and vast executive experience with the AOS. We look forward to learning from him.”
Dr. Grossniklaus achieved board certification by the ABO in 1985 and participates in the Continuing Certification program, designed to help keep ophthalmologists up to date in clinical knowledge and skills.